Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine

Published:2019-05-31 Issue:6 Volume:19 Page:461-471
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Van Den Borg Robin¹,Leonetti Alessandro¹²,Tiseo Marcello²³,Giovannetti Elisa¹⁴,Peters Godefridus J.¹

Affiliation:

1. Laboratory Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, Netherlands

2. Medical Oncology Unit, University Hospital of Parma, Parma, Italy

3. Department of Medicine and Surgery, University of Parma, Parma, Italy

4. Cancer Pharmacology Lab, AIRC Start-Up Unit, Pisa, Italy

Funder

Italian Association for Cancer Research

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://tandfonline.com/doi/pdf/10.1080/14737140.2019.1624530

Reference102 articles.

1. Cancer statistics, 2019

2. Mutational signatures associated with tobacco smoking in human cancer

3. Comprehensive genomic profiles of small cell lung cancer

4. Small cell lung cancer: Where do we go from here?

5. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease?

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors;Science Advances;2024-01-19

2. DNA repair pathways in breast cancer: from mechanisms to clinical applications;Breast Cancer Research and Treatment;2023-06-08

3. Induced Degradation of Lineage-specific Oncoproteins Drives the Selective PARP1 Inhibitor Toxicity in Small Cell Lung Cancer;2022-11-03

4. Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy;Lung Cancer: Targets and Therapy;2022-09

5. Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy;LUNG CANCER-TARGETS;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3